What kind of company is Big Ten Cancer Research Consortium?

The Big Ten Cancer Research Consortium is a group of academic medical centers from across the United States that have come together to conduct groundbreaking cancer research. Founded in 2013, the consortium includes more than a dozen member institutions, all of which are part of the Big Ten academic conference.

The consortium's mission is to improve cancer treatment and patient outcomes by leveraging the resources and expertise of its member institutions. By working collaboratively on clinical trials and other research projects, the consortium aims to accelerate the development of new cancer therapies and advance our understanding of the disease.

One of the key strengths of the Big Ten Cancer Research Consortium is the diversity of its member institutions. From large medical centers to smaller universities, the consortium brings together a wide range of expertise and resources, allowing for more comprehensive and effective research.

To date, the consortium has conducted more than 200 clinical trials spanning multiple cancer types, including breast, lung, colorectal, and prostate cancer. These trials have investigated a wide range of treatments, from traditional chemotherapy to newer immunotherapy and targeted therapy approaches.

Overall, the Big Ten Cancer Research Consortium represents a powerful collaboration at the forefront of cancer research. By working together, its member institutions are making significant strides towards a future where cancer is no longer a life-threatening disease.